Online inquiry

IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15392MR)

This product GTTS-WQ15392MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD37 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001040031.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 951
UniProt ID P11049
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ15392MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9480MR IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IPH-5401
GTTS-WQ3485MR IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BA1126
GTTS-WQ6433MR IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CT-P22
GTTS-WQ3927MR IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BCD-145
GTTS-WQ8267MR IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HM10560A
GTTS-WQ3653MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 1187982
GTTS-WQ5304MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ13971MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN3470-3471-3479
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW